新辅助化疗联合手术治疗可切除或交界可切除胰腺癌患者的临床疗效

doi:10.3969/j.issn.1671-7171.2026.07.018

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1311 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】探讨新辅助化疗联合手术治疗可切除或交界可切除胰腺癌患者的临床疗效。【方法】70例胰腺癌患者,其中35例接受手术治疗的患者作为对照组,35例接受新辅助化疗联合手术治疗的患者为观察组。比较两组患者围手术期指标,术后1年、术后3年的生存情况。【结果】两组患者的肿瘤直径、手术方式、手术时间、术后住院时间及术后并发症发生率比较,差异均无统计学意义(P>0.05);观察组术后1年生存率和术后3年生存率均高于对照组,生存时间长于对照组(P<0.05);观察组术后总转移率和局部复发率均低于对照组(P<0.05)。【结论】新辅助化疗联合手术治疗在可切除及交界可切除胰腺癌中具有良好的安全性,不增加围手术期风险。该方案能显著延长患者生存时间,降低局部复发与远处转移率,具有较高的临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	江冬容

关键词 ：胰腺肿瘤, 化学疗法,辅助, 外科手术

Abstract：【Objective】 To investigate the clinical efficacy of neoadjuvant chemotherapy combined with surgery in patients with resectable and borderline resectable pancreatic cancer. 【Methods】 A total of 70 patients with pancreatic cancer were enrolled in this study. Thirty-five patients who underwent surgery alone were assigned to the control group, while 35 patients who received neoadjuvant chemotherapy followed by surgery were assigned to the observation group. Perioperative outcomes and survival rates at 1 and 3 years postoperatively were compared between the two groups. 【Results】 There were no statistically significant differences between the two groups in terms of perioperative indicators including tumor diameter, surgical procedure, operative time, postoperative hospital stay, and postoperative complications (P>0.05). The 1-year and 3-year postoperative survival rates in the observation group were significantly higher than those in the control group, and the overall survival time in the observation group was significantly longer than that in the control group (P<0.05). In addition, the overall metastasis rate and local recurrence rate after surgery in the observation group were significantly lower than those in the control group (P<0.05). 【Conclusion】 Neoadjuvant chemotherapy combined with surgery is safe and feasible for patients with resectable and borderline resectable pancreatic cancer and does not increase perioperative risks. Moreover, it can significantly improve postoperative survival rates, prolong survival time, and effectively reduce local recurrence and distant metastasis rates, demonstrating substantial clinical value.

Key words： Pancreatic Neoplasms Chemotherapy,Adjuvant Surgery

收稿日期: 2025-08-14

中图分类号:

R735.9

引用本文:

江冬容. 新辅助化疗联合手术治疗可切除或交界可切除胰腺癌患者的临床疗效[J]. 医学临床研究, 2026, 43(7): 1120-1122.
JIANG Dongrong. Efficacy of Neoadjuvant Chemotherapy Combined with Surgery in Patients with Resectable and Borderline Resectable Pancreatic Cancer. JOURNAL OF CLINICAL RESEARCH, 2026, 43(7): 1120-1122.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2026.07.018 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2026/V43/I7/1120

[1] PARK W, CHAWLA A, O'REILLY E M. Pancreatic cancer: a review[J].JAMA,2021, 326(9):851-862.
[2] SIEGEL R L. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021, 71(3):209-249.
[3] 中华医学会外科学分会胰腺外科学组,中国研究型医院学会胰腺疾病专业委员会. 中国胰腺癌新辅助治疗指南(2020版)[J].协和医学杂志, 2020, 11(5):547-558.
[4] BIRRER D L, GOLCHER H, CASADEI R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care pooled data from 3 randomized controlled trials[J].Ann Surg,2021, 274(5):713-720.
[5] 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J].中华消化外科杂志, 2021, 59(7):713-729.
[6] SPRINGFELD C, FERRONE C R, KATZ M H G, et al. Neoadjuvant therapy for pancreatic cancer[J].Nat Rev Clin Oncol,2023, 20(5):318-337.
[7] LO W, ZUREIKAT A. Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials[J].Curr Opin Gastroenterol,2022, 38(5):521-531.
[8] ZHOU B, ZHANG S R, CHEN G, et al. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer[J].World J Gastroenterol,2023, 29(35):5094-5103.
[9] VAN DAM J L, JANSSEN Q P, BESSELINK M G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials[J].Eur J Cancer,2022, 160(1):140-149.
[10] ALISEDA D, MARTí-CRUCHAGA P, ZOZAYA G, et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials[J].BJS Open,2024, 8(5):zrae087.
[11] AUGUSTINUS S, SCHAFRAT P J M, JANSSEN B V, et al. Nationwide impact of centralization, neoadjuvant therapy, minimally invasive surgery, and standardized pathology reporting on R0 resection and overall survival in pancreatoduodenectomy for pancreatic cancer[J].Ann Surg Oncol,2023, 30(8):5051-5060.
[12] BAI X L, LI X, CHEN Y W, et al. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: a randomized phase 3 trial[J].Cancer Cell,2025, 43(12):2259-2267.